GSK Consumer Healthcare Trading Profit Boosted 23% By Block Drug
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Block Drug acquisition drove trading profit for the consumer healthcare business up 23% to $798 mil. in 2001
You may also be interested in...
NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said
NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said
NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said